e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine

Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis.

Julie Labrosse; Marie Osdoit; Anne-Sophie Hamy; Florence Coussy; Jean-Yves Pierga; Fabien Reyal; Enora Laas · 2020 · PLoS ONE

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Although identified to be at a higher risk of relapse, no consensus exists on the treatment of breast cancer (BC) patients with no pathological complete response after neoadjuvant chemotherapy (NAC). The benefit of adjuvant chemotherapy (ADJ) in this context has scarcely been studied. We evaluated the benefit of administrating adjuvant chemotherapy in a real life cohort of BC patients with invasive residual disease after NAC. 1199 female BC patients with T1-3NxM0 invasive tumors receiving NAC at Institut Curie from 2002 to 2012 were included in the analysis. 1061 had been treated by NAC only,

Abstract by Julie Labrosse; Marie Osdoit; Anne-Sophie Hamy; Florence Coussy; Jean-Yves Pierga; Fabien Reyal; Enora Laas, PLoS ONE (2020) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.1371/journal.pone.0234173